Authors' recommendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of the proposed 21-gene expression profiling test, MSAC does not support public funding for its use to guide therapeutic decision making in breast cancer. MSAC also advised that it would be prepared to reconsider the application via the Evaluation Sub-Committee when the applicant has: - prospective data regarding the predictive value of the test beyond its prognostic value and thus its clinical utility in improving subsequent decisions about which patients should and should not receive adjuvant chemotherapy in addition to hormone therapy - further data regarding the gains in patient health outcomes from this clinical utility irrespective of the type of chemotherapy and hormone therapy - comparative data with other predictive tests available for breast cancer such as IHC-4 - addressed concerns over the high cost of the test, to both the government and the consumer.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1342-public

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Medical Services Advisory Committee

Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.

Contact Name: msac.secretariat@health.gov.au

Contact Email: msac.secretariat@health.gov.au

Copyright: Medical Services Advisory Committee (MSAC)